Alpelisib - Novartis Oncology

Drug Profile

Alpelisib - Novartis Oncology

Alternative Names: BYL-719; NVP-BYL-719

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Memorial Sloan-Kettering Cancer Center; Northwestern University; Novartis; Novartis Oncology; Peter MacCallum Cancer Centre; University Health Network
  • Class Amides; Antineoplastics; Dicarboxylic acids; Fluorine compounds; Pyridines; Pyrrolidines; Small molecules; Thiazoles
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Head and neck cancer; Multiple myeloma; Oesophageal cancer
  • Phase I Gastric cancer; Gastrointestinal stromal tumours; Pancreatic cancer; Rectal cancer; Uveal melanoma
  • Discontinued Solid tumours

Most Recent Events

  • 08 Jan 2018 UNICANCER plans the phase II SAFIR PI3K trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in February 2018 (NCT03386162)
  • 05 Dec 2017 Adverse events and efficacy data from the phase Ib portion of a phase Ib/II trial in Breast cancer presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)
  • 08 Nov 2017 Novartis withdraws a phase I/II trial prior to enrolment for Squamous cell cancer (Combination-therapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT02298595)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top